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Cleft lip and cleft palate (CLP) are common disorders that occur either as part of a syndrome, where struc-
tures other than the lip and palate are affected, or in the absence of other anomalies. Van der Woude syn-
drome (VWS) and popliteal pterygium syndrome (PPS) are autosomal dominant disorders characterized by
combinations of cleft lip, CLP, lip pits, skin-folds, syndactyly and oral adhesions which arise as the result
of mutations in interferon regulatory factor 6 (IRF6). IRF6 belongs to a family of transcription factors that
share a highly conserved N-terminal, DNA-binding domain and a less well-conserved protein-binding
domain. To date, mutation analyses have suggested a broad genotype–phenotype correlation in which mis-
sense and nonsense mutations occurring throughout IRF6 may cause VWS; in contrast, PPS-causing
mutations are highly associated with the DNA-binding domain, and appear to preferentially affect residues
that are predicted to interact directly with the DNA. Nevertheless, this genotype–phenotype correlation is
based on the analysis of structural models rather than on the investigation of the DNA-binding properties
of IRF6. Moreover, the effects of mutations in the protein interaction domain have not been analysed. In
the current investigation, we have determined the sequence to which IRF6 binds and used this sequence
to analyse the effect of VWS- and PPS-associated mutations in the DNA-binding domain of IRF6. In addition,
we have demonstrated that IRF6 functions as a co-operative transcriptional activator and that mutations in
the protein interaction domain of IRF6 disrupt this activity.
INTRODUCTION
Orofacial clefting (OFC) is a common developmental genetic
disorder that occurs with a prevalence which has been estimated
at between 1 in 500 and 1 in 2500 live births depending on geo-
graphic origin, racial and ethnic variation, and socio-economic
status (1,2). Individuals who exhibit OFC may experience pro-
blems with eating, speaking, hearing and facial appearance
which can be corrected to varying degrees by surgery, dental
treatment, speech therapy and psychosocial intervention. On
the basis that the lip/primary palate and the secondary palate
have distinct developmental origins, OFC can be divided into
cleft lip occurring either with or without cleft palate (CLP) and
isolated cleft palate in which the lip is not affected (CPO). This
division is validated on the basis that, under most circumstances,
CLP and CPO do not segregate in the same family (3). Although
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than the lip and palate are affected, over 70% of cases of CLP
and 50% of cases of CPO arise in the absence of other abnorm-
alities and are collectively classiﬁed as non-syndromic (4).
Recent data have been demonstrated that mutations in PVRL1,
MSX1, TBX22, IRF6 and FGFR1 are responsible for syndromic
forms of OFC (5–9) and that variation within these genes is a
contributoryfactortotheirnon-syndromiccounterparts(10–16).
Van der Woude syndrome (VWS; MIM 119300) is an auto-
somal dominant disorder of facial development which is
characterized by cleft lip, CLP and paramedian lower lip
pits (17). VWS is the most common form of syndromic
OFC, accounting for 2% of all cases, and has the phenotype
that most closely resembles the more common non-syndromic
forms. Popliteal pterygium syndrome (PPS; MIM 119500) has
a similar orofacial phenotype to VWS; however, PPS also
exhibits additional anomalies that include popliteal webbing,
pterygia, oral synychiae, adhesions between the eyelids, syn-
dactyly and genital anomalies (18,19). The VWS and PPS
loci were initially mapped to human chromosome 1q32–q41
(20–25) and both phenotypes were subsequently demonstrated
to result from mutations in the gene encoding interferon regu-
latory factor 6 (IRF6; Ref. 8). IRF6 belongs to a family of
transcription factors that share a highly conserved N-terminal,
penta-tryptophan, helix-turn-helix DNA-binding domain and a
less well-conserved protein-binding domain (8).
Initially, 46 mutations in IRF6 were identiﬁed in VWS
patients, with a further 13 being detected in families with a
history of PPS (8). Mutations that introduced a termination
codon into IRF6 were found to be signiﬁcantly more common
in VWS than in PPS consistent with haploinsufﬁciency being
the mechanism that underlies VWS (20,22,26). The missense
mutations that were observed in VWS and PPS fell into two dis-
tinct categories. Whereas the missense mutations underlying
VWS were almost evenly divided between the DNA-binding
and protein-binding domains, the vast majority of the missense
mutations found to be associated with PPS arose in the DNA-
binding domain. Moreover, comparison of the sequence of
IRF6 with that of IRF1 suggested that in the case of PPS every
amino acid residue mutated contacted DNA directly, whereas
only a small minority of the residues mutated in VWS individ-
uals made direct contact with DNA. While this genotype–
phenotypecorrelationhasbroadlybeensupportedbysubsequent
studies, it is based solely on the analysis of structural models
rather than on a systematic investigation of the DNA-binding
properties of IRF6. Moreover, the effects of mutations in the
protein interaction domain have not been investigated.
In the current investigation, we have determined the DNA-
binding sequence to which wild-type IRF6 binds and used this
sequence to determine the effect of VWS- and PPS-associated
mutations in the DNA-binding domain of IRF6. In addition,
we have demonstrated that IRF6 functions as a co-operative
transcriptional activator and that VWS-causing mutations in
the protein interaction domain of IRF6 disrupt this activity.
RESULTS
Identiﬁcation of an IRF6 DNA-binding site
To investigate the effects of disease-causing mutations in the
IRF6 DNA-binding domain (IRF6-DBD), we ﬁrst sought to
identify a DNA-binding sequence to which the wild-type
protein would bind. Various IRF6 constructs (amino acids
1–113; 1–225; 1–401; 1–467), all of which contained the
DNA-binding domain (amino acids 13–113), were expressed
as N-terminal, His-tagged fusion proteins in E. coli and puri-
ﬁed to homogeneity using a single-step, Ni-afﬁnity column
(Fig. 1A). Members of the IRF family of transcription
factors are known to bind to a number of consensus sites, as
shown for the DNA-binding domain of IRF1 (Fig. 1B). To
determine whether IRF6 could bind to a subset of these
sites, electrophoretic mobility shift assays were performed
using degenerate, double-stranded oligonucleotides corre-
sponding to three potential response elements. Only the
IRF6 construct composed of amino acids 1–113 caused a
gel shift, demonstrating that each pool of sites contains
sequences to which IRF6-DBD can bind (Fig. 1B, lanes
7–9). An identical result was obtained using in vitro translated
proteins (data not shown).
To identify the consensus DNA-binding site for the
IRF6-DBD, all permutations of the IRF-E pool of sequences
were subsequently synthesized and one site was selected to aid
isolation of additional sites using an unbiased, PCR-based, site-
selectionassay.Afterfourrounds,theselectedpoolofDNAwas
cloned and 23 sequences determined (Fig. 2A and B). The
sequences were subsequently used to derive the consensus
binding site for the IRF6-DBD (Fig. 2C). To conﬁrm that the
selected sites were a true reﬂection of the IRF6 binding speci-
ﬁcity, several individual sequences were tested in electrophore-
ticmobilityshiftassays;allsitestestedwereboundefﬁcientlyby
IRF6 (Fig. 2D). To analyse the speciﬁcity of the identiﬁed core
consensus sequence –AACCGAAAC
C/T, single base pair
changes in the S17 sequence were investigated using EMSA
(Fig. 2E). Whereas an A.T substitution at position 7 permitted
binding, an A.C substitution at this position abrogated DNA
binding (Fig. 2E, lanes 1–3). Similar approaches indicated that
while substitution of cytosine at position 4, which was invari-
ant in the site selection assay, could not be tolerated (Fig. 2E,
lane 4), a C.G substitution at position 9 of the extended core
sequence permitted DNA binding, albeit with lower afﬁnity
(Fig. 2E, lane 5). Collectively, these data indicate that the
Figure 1. IRF6 DNA-binding domain binds to ISRE sites. (A) SDS–PAGE
gel showing puriﬁcation of the IRF6 DNA-binding domain (IRF6-DBD).
The protein was puriﬁed by Nickel-afﬁnity chromatography. Fractions from
each of the puriﬁcation stages are shown as indicated above the lanes. Lane
5 contains the pure protein which was subsequently used to select the IRF6
consensus sequences. (B) EMSA showing DNA binding to the three pools
of degenerate ISRE sequences as indicated above the lanes. The IRF6-DBD/
DNA complexes are indicated by the arrow.
536 Human Molecular Genetics, 2009, Vol. 18, No. 3IRF6-DBD possesses speciﬁc, high afﬁnity binding to the con-
sensus sequence AACCGAAAC
C/T in vitro.
The majority of the mutations found in the IRF6
DNA-binding domain of VWS/PPS patients inhibit
DNA binding
To determine the effect of VWS- and PPS-associated
mutations that arise in the DNA-binding domain of IRF6,
the ability of IRF6 mutant proteins to bind to the derived
IRF6 DNA-binding site was investigated. Speciﬁc disease-
causing mutations were introduced into the IRF6-DBD and
their ability to affect DNA binding was determined using
both puriﬁed protein and in vitro translated protein; an equal
amount of each mutant protein, as determined by Coommassie
Blue staining or phosphorimaging, respectively, being incu-
bated with radio-labelled DNA containing the IRF6 binding
site (Fig. 3B). When compared to the wild-type protein, 12
of the 13 disease-causing mutations tested abrogated DNA
binding; notably, the Gly70Arg mutation, which underlies
VWS, had little effect on DNA binding (Fig. 3B). These ﬁnd-
ings suggest that the majority of mutations in VWS and PPS
Figure 2. Selection of a consensus DNA-binding site for IRF6. (A) EMSA analysis of the selected pools of binding sites using bacterially expressed IRF6-DBD.
The starting double-stranded DNA is shown in lane 0. The free DNA represents the DNA pool after the indicated number of rounds of selection. The positiono f
the protein-DNA complex is shown (arrow). The DNA from the complexes in lane 3 was ampliﬁed and cloned for sequence analysis. (B) Sequences of the
DNA-binding sites selected by IRF6 after three rounds of selection. Nucleotides derived from the random sequence (upper case) and the constant ﬂanking
primers (lower case) are indicated. The IRF core sequence is underlined in each sequence. Sites are aligned and orientated according to this IRF core sequence.
(C) A schematic sequence representation for IRF6 binding sites after three rounds of selection. (D) EMSA showing IRF6-DBD binding to individual sequences
obtained in the site selection. Lane 1 contains the initial sequence obtained from the IRF-E pool. The identity of each of the selected sites is shown above the
lanes. (E) EMSA showing speciﬁc binding of IRF6-DBD to the S17 site and its variants containing speciﬁc point mutations. The identity of each of the sites is
shown above the lanes. The core sequences are shown below the panel and the mutated bases are underlined.
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function of IRF6; however, this appears not to be the only
mechanism by which mutation of the IRF6 DNA-binding
domain can cause disease since the Gly70Arg mutant binds
DNA avidly.
The effect of missense mutations on the structure of the
IRF6 DNA-binding domain
The distribution of missense mutations in the IRF6 DNA-
binding domain differs signiﬁcantly between PPS and VWS
(8; unpublished data), suggesting that different mutations
confer different effects on the function of IRF6. To establish
whether there is a simple correlation between the disease phe-
notype and the extent to which a mutation disrupts the struc-
ture of the DNA-binding domain, we performed protein
modelling and biochemical analyses of mutant isoforms.
We performed protein modelling for the wild-type and
Arg84 and Gly70 mutant isoforms of the DNA-binding
domain. In wild-type IRF6, the side chain of Arg84 is
involved in two hydrogen bonds with the DNA phosphate
backbone (Fig. 4A). Mutating this arginine residue to
glycine, proline, cysteine or histidine ablated these hydrogen
bonds (Fig. 4A). In addition to the disruption of hydrogen
bonding, proline, cysteine and glycine possess much smaller
amino acid side-chains than arginine; therefore, the area of
the DNA-protein interface was reduced with these mutations.
While the glycine, cysteine and histidine mutations were not
likely to have a large effect on the tertiary structure of the
DNA-binding domain, the Arg84Pro mutation has the poten-
tial to disrupt the secondary structure of helix three of IRF6.
Proline residues are frequently associated with distortion of
alpha-helices, as predicted above. Gly70 is not involved in
the DNA-binding interface and is in loop region (L2)
between helices 2 and 3 (Fig. 4B). Mutation of Gly70 to argi-
nine made no obvious alterations to the protein structure
although effects on inter- and intra-molecular interactions
cannot be excluded (Fig. 4B).
As a direct test for differences in structural effects
between PPS- and VWS-associated mutations, we per-
formed circular dichromism (CD) analysis on mutant iso-
forms of the IRF6-DBD. Arg84Cys and Arg84His
mutations are found in both VWS and PPS patients,
whereas Arg84Pro and Arg84Gly occur in patients affected
by VWS. The CD spectra of the Arg84Cys, Arg84His and
Arg84Gly proteins were almost identical to that of the wild-
type protein (Fig. 5). In contrast, the spectrum of the
Arg84Pro mutant was consistent with a severely disrupted
structure. To test whether the loss of structure in the
Arg84Pro was due to inherent instability or simply an
inability of this mutant isoform to refold in vitro, we per-
formed CD analyses on a second set of IRF6-DBD proteins
that were puriﬁed directly from bacteria without a denatura-
tion/renaturation protocol. In this case, the CD spectra for
Figure 3. DNA binding of VWS and PPS mutants. (A) The amino acid sequence of the IRF6 DNA-binding domain; a subset of mutations found in VWS and PPS
patients are shown above the wild-type residue. (B) EMSA showing DNA binding of the mutant IRF6-DBD proteins depicted in (A). In vitro translated proteins
were incubated with the consensus sequence shown above the panel. Lane 1 contains the wild-type IRF-DBD protein (WT). The identity of each mutant protein
is indicated above the lanes; V18A, V18M, G70R, P76S, R84G, R84P, D98H and D98V are VWS-causing mutations: L22P and W60G are PPS-causing
mutations; R84C, R84H and K89E underlie both VWS and PPS.
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wild-type (data not shown). To test for subtle differences
in stability, we performed a thermal titration curve for
each. The inﬂection points for the four mutants were
similar, and all were slightly higher than the wild-type (Sup-
plementary Material, Fig. S1), suggesting that all the mutant
isoforms are more stable, not less stable, than the wild-type.
These data suggest that the extent to which a mutation dis-
rupts the overall structure of the IRF6 DNA-binding domain
does not simply correlate with the disease phenotype. Intri-
guingly, the Gly70Arg mutation, which was the only
mutation examined that does not abrogate DNA binding,
also exhibited a similar spectrum to the wild-type protein
(Fig. 5).
Identiﬁcation of the transcriptional activation
domain of IRF6
Initial experiments established that the expression of IRF6 in
COS-7 cells did not activate a luciferase reporter plasmid con-
taining ﬁve copies of the IRF6 binding site (data not shown).
Subsequent analysis of the sub-cellular localization of an
EGFP-IRF6 fusion protein demonstrated that it resides in the
cytoplasm (Supplementary Material, Fig. S2); this is analogous
to the situation with IRF3, which is also cytoplasmic and
requires viral infection to induce its nuclear translocation
(27). Since we have so far been unable to determine the acti-
vation signal for IRF6, we used the GAL4-DBD reporter
system to investigate the functional effects of disease-causing
mutations within the protein-binding domain of IRF6. IRF6
was fused to the GAL4-DBD, and its ability to regulate tran-
scription from the LEXA-VP16/GAL4 reporter plasmid was
determined (Fig. 6A). The LEXA-VP16/GAL4 reporter con-
struct has been used previously to assess the ability of a tran-
scription factor to activate or repress transcription; it contains
multiple GAL4 and LEXA binding sites upstream of the
SV40 promoter. Transcriptional activation can be determined
by co-transfection with a GAL4 fusion protein alone;
however, if the GAL4 fusion protein is a repressor then this
can be assessed by activating the reporter with the
LEXA-VP16 activator. When the expression plasmid encoding
the full-length IRF6 protein fused to the GAL4-DBD,
GAL-IRF6-(1–467) was co-transfected with the luciferase
reporter plasmid and activation was observed (Fig. 6B);
Figure 4. (A) Homology model of IRF6-DBD shown in red cartoon representation revealing a close-up of helix 3 after energy minimization The DNA is shown
in green. Panel (i) shows the position of Arginine 84 in blue; panels (ii), (iii), (iv) and (v) show the mutations R84H, R84C, R84P and R84G, respectively. In each
case, the Van der Waals surface around residue 84 is indicated with blue dots. (B) The position of the G70R mutation is shown, highlighting the distance of this
residue from the DNA. Colour scheme as in (A).
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presence of the LEXA-VP16 activator (Fig. 6B). These obser-
vations suggest that IRF6 acts as a co-operative transcriptional
activator.
To map the activation domain of IRF6, a series of
N-terminal deletions were generated and their ability to acti-
vate transcription determined (Fig. 6A and B). Deletion of
the N-terminal region to residue 113 resulted in a 4-fold
increase in transcriptional activation, while deletion to
residue 226 resulted in greater than a 5-fold increase
(Fig. 6B). Additional deletions into the protein-binding domain
resulted in a reduction in activity. These data suggested that
the transcriptional activation domain resides between residues
226 and 467; this was supported further by the observation
that titration of increasing amounts of GAL-IRF6-(226–467)
resulted in increased transcriptional activation (Fig. 6C).
Mutations found in the IRF6 transcriptional activation
domain of VWS and PPS patients inhibit
transcriptional activation
Numerous mutations have been found in the protein-binding
domain of IRF6 in VWS patients. To determine the effect of a
subset of these mutations on the transcriptional activation func-
tion of IRF6, speciﬁc mutations were introduced into
GAL-IRF6-(226–467) and their ability to affect transcriptional
activation was determined using a luciferase reporter assay
(Fig. 7). Of the seven mutations tested, six (Arg250Gln,
Arg250Gly, Leu294Pro, Cys374Arg and Gly376Arg) inhibited
transcriptional activation completely, while one (Lys320Glu)
stimulated activation above that of the wild-type (Fig. 7). The
polymorphism Val274Ile, which has been demonstrated to be
signiﬁcantly associated with non-syndromic cleft lip and
palate but which is not the disease-causing variant (14), had
little effect on transcriptional activity.
DISCUSSION
The IRFs are a family of nine transcription factors that share a
highly conserved, N-terminal, helix-turn-helix DNA-binding
domain and a more variable protein-binding domain. The sig-
nature motif of the DNA-binding domain is a tryptophan
repeat consisting of ﬁve residues spaced at 10–18 amino
acid intervals (28). In the current study, we have used a site-
selection assay to demonstrate that IRF6 binds to the core con-
sensus sequence 50-AACCGAAAC
C/T-30 which conforms to
the IRF-E (50-GAAAA
G/C
T/CGAAA
G/C
T/C-30), ISRE (50-
A/GNG
AAANNGAAACT-30) and minimal core (50-AANNGAAA-30)
sequences to which other IRF family members bind (29–31).
Crystallization studies have shown that the DNA-binding
domain of IRF1 has a helix-turn-helix motif that latches
onto DNA through three of the ﬁve conserved tryptophan resi-
dues. The motif selects a short GAAA core sequence, binding
to which is mediated by four amino acid residues; Arg82,
Cys83, Asn86 and Ser87 (32); the equivalent residues in
IRF6 are Arg84, Cys85, Asn88 and Lys89. Intriguingly, the
substitution of serine by lysine at position 87 of IRF1, which
is also observed in IRF4, IRF5, IRF8 and IRF9, confers the
potential to reach over and mediate binding outside the
GAAA core sequence (32,33). In the current study, we have
demonstrated that the substitution K89S abrogates DNA
binding (data not shown) conﬁrming that IRF6 is a member
of the same sub-group of IRFs as IRF4, IRF5, IRF8 and
IRF9; consequently, the modelling studies reported here
were based on the crystal structure of IRF4 rather than that
of IRF1 (8). Interestingly, only the IRF6 construct containing
amino acids 1–113 exhibited DNA binding. This situation
mirrors that of IRF3 which uses an auto-inhibitory mechanism
to suppress its transactivation potential, phosphorylation
resulting in the alteration of the IRF3 structure which sub-
sequently leads to unmasking of the hydrophobic active site
and realignment of the DNA-binding domain for transcrip-
tional activation (34).
Previous studies have demonstrated that mutations in IRF6
underlie VWS and PPS which are characterized by varying
degrees of cleft lip, CLP, lip pits, skin-folds, syndactyly and
oral adhesions (17–19). Murray and colleagues initially
demonstrated that the distribution of mutations in IRF6 was
non-random; for example, protein truncation mutations,
while common in VWS, were rare in PPS (8). Similarly,
while the missense mutations found in VWS were distributed
between the DNA-binding domain and the protein-binding
domain, those underlying PPS were predominantly found in
the DNA-binding domain. In addition, the distribution of
VWS/PPS mutations in the DNA-binding domain was
skewed with residues that were predicted to contact DNA
being mutated more commonly. Subsequently, these studies
have been extended with 219 mutations having been identiﬁed
in VWS families and 36 PPS-causing mutations being
described (unpublished data). Comparison of the position
and type of mutation with the clinical diagnosis in these
families has supported the broad genotype–phenotype corre-
lation; nevertheless, as outlined below, some exceptions to
the general principles have been noted.
In the current study, 12 of the 13 DNA-binding domain
mutations analysed were found to abrogate DNA binding,
Figure 5. Circular dichroism spectra of puriﬁed recombinant wild-type (WT)
and mutant IRF6 proteins. The identity of each mutant protein is indicated in
the key.
540 Human Molecular Genetics, 2009, Vol. 18, No. 3the single exception being the mutation Gly70Arg which has
been demonstrated to underlie VWS in two unrelated families
and has not been reported to be a single nucleotide poly-
morphism (8). The CD spectra generated for the DNA-binding
domain containing the Gly70Arg mutation were very similar
to those of the wild-type polypeptide, indicating that no
gross conformational change is induced. It is, therefore, poss-
ible that this particular mutation exerts its effect by disrupting
the conformation of the full-length protein, perhaps via intra-
molecular interactions between domains, or by affecting the
interactions with a putative co-regulator.
The residue Arg84 is a clear mutational hotspot for PPS.
Initially, mutations in Arg84, particularly Arg84Cys and
Arg84His, which are predicted to result in a complete loss
of contact with the core consensus sequence GAAA (8),
were thought to cause solely PPS; however, recent evidence
has shown that these mutations may also result in VWS
(unpublished data). These combined results demonstrate that
while the association between the Arg84Cys and Arg84His
mutations and PPS is strong, it is not absolute. Moreover,
VWS has also been shown to result from the mutations
Arg84Gly and Arg84Pro (35; unpublished data). In the
current study, we have demonstrated that all four mutations
result in loss of DNA binding; consequently, the Arg84Gly
and Arg84Pro mutations challenge the hypothesis that PPS
results from a dominant negative mechanism via the formation
of inactive transcription complexes (8). Nevertheless, a direct
assessment of dominant-negative activity was not conducted
in the current study and it is also possible that different
mutations have template-speciﬁc effects. Despite these obser-
vations, it is notable that the residue Arg84 is located in the
middle of helix 3 of the DNA-binding domain of IRF6 and
that the amino acids proline and glycine are known to
disrupt alpha helices (36). The tolerance of the Arg84Gly
mutation in the alpha-helix, as demonstrated by CD analysis
(Fig. 5), may be the consequence of the surrounding sequence;
glycine is more readily tolerated in a helix than proline
depending on the local sequence environment. In addition,
longer helices having extensive intra-molecular hydrogen
bonding networks may compensate for the tendency of
glycine to break the helix. Conversely, proline as a helix
terminating motif is far less ambiguous than glycine, and the
Arg84Pro mutant DNA-binding domain was not able to
refold; in particular, proline residues ﬂanked by polar amino
Figure 6. IRF6 activates transcription. (A) Wild-type IRF6 and a series of N-terminal deletions were fused to the C-terminus of the GAL4 DNA-binding domain
as depicted. The DNA-binding and the protein interaction domains are indicated. The positions of the N- and C-terminal amino acids are shown for each of the
IRF6 derivatives. (B) The graph shows activation of the luciferase reporter by the GAL-IRF6 proteins in the presence and absence of a ﬁxed amount of
LEXA-VP16 as indicated by þ and 2, respectively. The identity of the GAL fusion proteins in each transfection is indicated below the x-axis. All transfections
were performed in triplicate; luciferase activities are presented as means with standard errors shown. All values are relative to the activity of the reporter plasmid
alone. (C) Titration of increasing amounts of GAL-IRF6-(226-467). The graph shows activation of the luciferase reporter by the GAL-IRF6-(226-467) protein in
the presence and absence of a ﬁxed amount of LEXA-VP16 as indicated by þ and 2, respectively. 0, 10, 100 and 300 ng of GAL-IRF6-(226-467) were trans-
fected. All transfections were performed in triplicate; luciferase activities are presented as means with standard errors shown. All values are relative to the
activity of the reporter plasmid alone.
Figure 7. The effect of VWS and PPS mutations on the function of the IRF6
transactivation domain. (A and B) The graphs show activation of the luciferase
reporter by the wild-type (WT) and mutant GAL-IRF6-(226-467) proteins in
the presence and absence of a ﬁxed amount of LEXA-VP16 as indicated
by þ and 2, respectively. The identity of each mutation is indicated below
the x-axis. All transfections were performed in triplicate; luciferase activities
are presented as means with standard errors shown. All values are relative to
the activity of the reporter plasmid alone.
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However, CD data generated with the native Arg84Pro
mutant isoform showed CD spectra and thermal stability that
were similar to wild-type. It appears that the stabilization
energy when using a correctly folded domain as the starting
point was too great to disrupt the domain in silico and
in vivo. Consequently, if Arg84Pro and Arg84Gly mutations
cause VWS by disrupting the secondary structure of IRF6
leading to a complete loss of IRF6 function, then that
change is not detectable in the context of the DNA-binding
domain alone; rather, future experiments must be designed
to interrogate the effect of altered secondary structure in the
context of the whole protein.
Despite these observations, the mutation L22P, which
affects an amino acid residue that is not predicted to contact
DNA, has been shown to result in VWS or PPS in members
of the same family (37). These ﬁndings indicate that the
genotype–phenotype correlation in man is not absolute and
suggest that a clinical continuum exists with the precise phe-
notype being determined by a combination of the causative
mutation, genetic background and stochastic factors. Intrigu-
ingly, this situation is mirrored in mice carrying either an
Arg84Cys mutation, in which IRF6 protein while generated
lacks the ability to bind DNA, or mice carrying a null mutation
in Irf6 (38,39). While in both lines, homozygous mutant
mice display an identical phenotype comprising a hyper-
proliferative epidermis that fails to undergo terminal differen-
tiation resulting in multiple soft tissue fusions, the phenotype
of the Irf6þ/R84C mice, which exhibited mild intra-oral adhe-
sions, is more severe and displays greater penetrance than
that reported for the Irf6-null mice, despite both mutations
being on the same genetic background (38,39).
As a prelude to examining the effect of disease-causing
mutations in the protein-binding domain of IRF6, we have
analysed the ability of IRF6 to act as a transcriptional regula-
tor. Our initial experiments demonstrated that IRF6 localized
to the cytoplasm and, consequently, was unable to activate a
luciferase reporter containing multiple copies of its consensus
binding site. The cytoplasmic localization of IRF6 has been
reported previously (40). This situation parallels that of
IRF3 which also localizes in the cytoplasm as an inactive
monomer maintained by auto-inhibitory domains that ﬂank
the protein-interaction domain until virus-induced phosphoryl-
ation converts IRF3 into an active monomer that enters the
nucleus to activate transcription of its target genes (27,34).
While we have not, as yet, identiﬁed the signal that results
in phosphorylation of IRF6 with subsequent nuclear transloca-
tion, transforming growth factor b3 is a potential candidate for
this role, at least in the secondary palate where Irf6 has been
shown to be down-regulated in the medial edge epithelia of
the developing palatal shelves in both Tgfb3 and Tgfbr2
mutant mice (41,42). As a consequence of these ﬁndings, we
used the GAL4-DBD reporter system to demonstrate that
IRF6 acts as a co-operative transcriptional activator. In this
study, we have used the minimal VP16 activation domain in
a standard synergy assay; however, VP16 is unlikely to be a
natural co-operative partner of IRF6 such partners remaining
to be identiﬁed. This situation has also been described for
the ETS family member PU.1 and IRF4 which co-operatively
bind to composite elements found in the promoters and
enhancers of b-lymphoid and myeloid genes (43–45). Impor-
tantly, while all seven of the VWS-causing mutations analysed
either decreased (Arg250Gln, Arg250Gly, Leu294Pro,
Cys374Arg, Gly376Arg) or increased (Lys320Glu) the tran-
scriptional activation function of IRF6, the neutral polymorph-
ism Val274Ile had no effect on this activity. In the case of
Lys320Glu, it is important to note that this mutation has
been described in two unrelated families (8), the mutation
arising as a de novo event in one of these families thereby sup-
porting the hypothesis that Lys320Glu is pathogenic rather
than a polymorphism.
One of the goals of our research is to dissect the molecular
pathway in which IRF6 functions during development of the
lip and palate. To date, a combination of human genetic ana-
lyses and developmental studies has led to the identiﬁcation of
two transcription factors which act upstream of IRF6.
Recently, Murray and colleagues identiﬁed a common func-
tional variant in an AP-2a binding site within an IRF6 enhan-
cer that showed highly signiﬁcant linkage disequilibrium with
isolated cleft lip, but not with cleft lip and palate or isolated
CLP (46). Electrophoretic mobility shift assays and chromatin
immunoprecipitation subsequently demonstrated that the risk
allele disrupts binding of AP-2a to the IRF6 enhancer (46).
Importantly, TFAP2A, which encodes AP-2a, maps to
human chromosome 6p24 within a region where chromosomal
anomalies have been associated with OFC (47,48) and
mutation of Tfap2a in mice results in facial anomalies
(49,50). Similarly, the transcription factor P63 has been
demonstrated to bind to a consensus P53-response element
within IRF6 while Tp63 and Irf6 interact genetically during
development of the secondary palate (unpublished data).
Although these studies have identiﬁed transcription factors
that lie upstream of IRF6 during craniofacial development,
the downstream targets of IRF6 remain uncharacterized; in
this context, delineation of the consensus IRF6 binding site
detailed in the current study will facilitate the identiﬁcation
of putative transcriptional targets of IRF6.
MATERIALS AND METHODS
Plasmid construction and site-directed mutagenesis
Fragments of Irf6 were ampliﬁed from embryonic day 14
mouse cDNA using the primers listed in Supplementary
Material, Table S1 and cloned into either pET-14b for electro-
phoretic mobility shift assays or pSG424 for luciferase assays.
Disease-causing mutations were generated using the primers
listed in Supplementary Material, Table S2 and the ‘Quick
Change’ site-directed mutagenesis kit (Stratagene) according
to manufacturer’s instructions. All constructs were veriﬁed
using sequence analysis.
Electrophoretic mobility shift assays
The radio-labelled DNA was subjected to electrophoresis on a
10% non-denaturing polyacrylamide gel, excised and puriﬁed
using a G-50 micro-column according to the manufacturer’s
instructions (Probe Quant). The probe was incubated at
room temperature for 30 min with IRF6 protein in the pre-
sence of binding buffer [20 mM Tris, pH 7.5; 50 mM NaCl;
542 Human Molecular Genetics, 2009, Vol. 18, No. 31m M EDTA; 5% glycerol; 5 mM dithiothreitol; 1 mg bovine
serum albumin and 100 ng poly(dI:dI)-poly(dI:dC)]. The
DNA-protein complexes were resolved on a 5% polyacryl-
amide gel in 1  TBE for 3 h at 180 V. The resulting gels
were ﬁxed in 10% acetic acid/20% methanol solution for
20 min, dried and subjected to autoradiography.
Protein production
The coding region of the IRF6 DNA-binding domain
(IRF6-DBD; amino acids 1–113) was ampliﬁed by PCR
from mouse cDNA derived from embryonic day 14 using
primer pairs 50-GATCCATATGGCCCTCCACCCTCGAAG
AG-30 and 50- GATCGGATCCTCACACTTGATAGATCTT
CACAGG- 30. The PCR ampliﬁed product was cloned into
pET-14b in order to fuse a hexahistidine tag to the N-terminus
of the expressed protein. The resultant plasmid,
pET-IRF6-DBD, was used to transform E. coli BL21 cells
and expression was induced using 1 mM IPTG for 3 h. The
recombinant protein was expressed in the insoluble fraction
and puriﬁed under denaturing conditions using the Ni-NTA
spin kit according to the manufacturer’s instructions
(Qiagen). The puriﬁed protein was visualized by SDS–
PAGE to determine the molecular size, protein integrity and
yield. Protein refolding was achieved by dialysing 100 mlo f
puriﬁed protein against solutions of decreasing denaturant
using a 7000 MW Slide-A-Lyzer mini dialysis unit (Pierce).
Dialysis was performed for 24 h against each of the following
solutions: 2 M GuHC1, 50 mM HEPES, 500 mM KCl, 10 mM
DTT; 1 M GuHCl, 50 mM HEPES, 500 mM KCl, 10 mM DTT;
0.5 M GuHCl, 50 mM HEPES, 500 mM KCl, 10 mM
DTT. Final dialysis was against 50 mM HEPES, 500 mM
KC1, 10 mM DTT for 12 h. In vitro translated IRF6 proteins
were generated using a TNT kit and T7 polymerase according
to the manufacturer’s instructions (Promega).
Determination of IRF6 binding sequence
The putative core binding sequence for IRF members is pro-
posed to be AANNGAAA (31). Three IRF consensus binding
sites containing this sequence were synthesized; ISRE1:
GAAANNGAAANN; IRF-E: GAAA
G/C
C/TGAAA
G/C
T/C and
ISRE3:
A/GNGAAANNGAAACT (29,30) and used in electro-
phoretic mobility shift assays with the His-tagged IRF6-DBD.
Subsequently, all 16 possible sequence combinations of the
IRF-E site were synthesized and tested for their ability to
bind to IRF6-DBD. The consensus DNA-binding sequence
of IRF6 was determined as described previously (51). DNA
isolated from the ﬁnal round of selection was ligated into
the pDrive cloning vector using the PCR Cloning
plus kit
(Qiagen) according to the manufacturer’s instructions. Plas-
mids containing the 76 bp insert were sequenced and aligned
using WebLogo (52).
Circular dichroism analysis
Far-UV CD spectra were obtained using a Jasco J-810 spectro-
polarimeter equipped with a temperature-controlled quartz cell
with a path-length of 50 mm. Spectra were obtained between
190 and 260 nm at 208C obtaining an average of eight scans
for IRF6-DBD and mutants at concentrations ranging from
0.4 to 0.6 mg/ml. Buffer scans were subtracted, and concen-
trations normalized before analysis of the data using the
CDSSTR deconvolution algorithm in the software suite
Dichroweb (53).
Protein modelling
The structure of the DNA-binding domain from human
IRF4 (33) was used as the starting point for homology model-
ling of the IRF6 DNA-binding domain. All molecular
modelling was performed on a Linux workstation using the
Quanta2005 program (Accelrys Ltd). The model of the IRF6
DNA-binding domain was built based on the co-ordinates of
the IRF4 DNA-binding domain. The model was energy mini-
mized using steepest descents followed by the conjugate
gradient algorithm to convergence, removing bad steric and
electrostatic contacts. The Protein Health module was used
to check the integrity of the model using a Ramachandran
plot, and to identify buried hydrophilic or exposed hydro-
phobic residues and close contacts. Point mutations corre-
sponding to Arg84Cys, Arg84His, Arg84Pro, Arg84Gly and
Gly70Arg were inserted into the IRF6 structure and molecular
dynamics performed using CHARMm.
Luciferase assays
COS-7 cells were maintained in DMEM containing 10% foetal
bovine serum. Once the cells had reached 80% conﬂuence,
they were transfected with 1 mg DNA (total) using Lipofecta-
mine 2000 according to the manufacturer’s instructions
(Invitrogen). Brieﬂy, 300 ng pSG424-IRF6 construct, 300 ng
LEXA-VP16, 300 ng ﬁreﬂy luciferase reporter and 100 ng
Renilla luciferase control pRL-CMV (Promega) were trans-
fected for 24 h. The cells were then lysed and luciferase
activity measured using the dual luciferase reporter assay
system following manufacturer’s instructions (Promega). All
transfections were performed in triplicate and standard errors
calculated. To ensure that appropriate IRF6 protein had been
expressed, equal amounts of COS-7 cell lysates were subjected
to electrophoresis on a 10% SDS–PAGE gel and subjected to
western blotting. The resulting nitrocellulose membrane was
incubated with a polyclonal anti-GAL4 antibody (Santa Cruz)
followed by an ECL peroxidase-labelled, anti-rabbit secondary
antibody (Amersham Biosciences) for the detection of the
IRF6-Gal4 complexes. Immunecomplexes were detected
using the ECL plus Western Blotting Detection System accord-
ing to the manufacturer’s instructions (Amersham Biosciences)
and exposed to x-ray ﬁlm.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
ACKNOWLEDGEMENTS
The authors thank Anthony Waldschmidt and Phyllis
Hemerson for technical assistance.
Human Molecular Genetics, 2009, Vol. 18, No. 3 543Conﬂict of Interest statement. The authors have no competing
interests.
FUNDING
This work was supported by Wellcome Trust (082868) and the
National Institutes of Health (P50-DE016215, DE13513).
REFERENCES
1. Vanderas, A.P. (1987) Incidence of cleft lip, cleft palate, and cleft lip and
palate among races: a review. Cleft Palate J., 24, 216–225.
2. Murray, J.C., Daack-Hirsch, S., Buetow, K.H., Munger, R., Espina, L.,
Paglinawan, N., Villanueva, E., Rary, J., Magee, K. and Magee, W. (1997)
Clinical and epidemiologic studies of cleft lip and palate in the
Philippines. Cleft Palate Craniofac. J., 34, 7–10.
3. Neilson, D.E., Brunger, J.W., Heeger, S., Bamshad, M. and Robin, N.H.
(2002) Mixed clefting type in Rapp-Hodgkin syndrome. Am. J. Med.
Genet., 108, 281–284.
4. Jones, M.C. (1988) Etiology of facial clefts: prospective evaluation of 428
patients. Cleft Palate J., 25, 16–20.
5. Suzuki,K.,Hu,D.,Bustos,T.,Zlotogora,J.,Richieri-Costa,A.,Helms,J.A.
and Spritz, R.A. (2000) Mutations of PVRL1, encoding a cell-cell adhesion
molecule/herpesvirus receptor, in cleft lip/palate-ectodermal dysplasia.
Nat. Genet., 25, 427–430.
6. van den Boogaard, M.J., Dorland, M., Beemer, F.A. and van Amstel, H.K.
(2000) MSX1 mutation is associated with orofacial clefting and tooth
agenesis in humans. Nat. Genet., 24, 342–343.
7. Braybrook,C.,Doudney,K.,Marcano,A.C.B.,Arnason,A.,Bjornsson,A.,
Patton, M.A., Goodfellow, P.J., Moore, G.E. and Stanier, P. (2001) The
T-box transcription factor gene TBX22 is mutated in X-linked cleft palate
and ankyloglossia. Nat. Genet., 29, 179–183.
8. Kondo, S., Schutte, B.C., Richardson, R.J., Bjork, B.C., Knight, A.S.,
Watanabe, Y., Howard, E., de Lima, R.L., Daack-Hirsch, S., Sander, A.
et al. (2002) Mutations in IRF6 cause Van der Woude and popliteal
pterygium syndromes. Nat. Genet., 32, 285–289.
9. Dode, C., Levilliers, J., Dupont, J.M., De Paepe, A., Le Du, N.,
Soussi-Yanicostas, N., Coimbra, R.S., Delmaghani, S.,
Compain-Nouaille, S., Baverel, F. et al. (2003) Loss-of-function
mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat.
Genet., 33, 463–465.
10. Sozen,M.A.,Suzuki,K.,Tolarova,M.M.,Bustos,T.,FernandezIglesias,J.E.
and Spritz, R.A. (2001) Mutation of PVRL1 is associated with sporadic,
non-syndromic cleft lip/palate in northern Venezuela. Nat. Genet., 29,
141–142.
11. Suzuki, Y., Jezewski, P.A., Machida, J., Watanabe, Y., Shi, M.,
Cooper, M.E., Viet Le, T., Nguyen, T.D., Hai, H., Natsume, N. et al.
(2004) In a Vietnamese population, MSX1 variants contribute to cleft lip
and palate. Genet. Med., 6, 117–125.
12. Jezewski, P.A., Vieira, A.R., Nishimura, C., Ludwig, B., Johnson, M.,
O’Brien,S.E.,Daack-Hirsch,S.,Schultz,R.E.,Weber,A.,Nepomucena,B.
et al. (2003) Complete sequencing shows a role for MSX1 in
non-syndromic cleft lip and palate. J. Med. Genet., 40, 399–407.
13. Marcano, A.C., Doudney, K., Braybrook, C., Squires, R., Patton, M.A.,
Lees, M.M., Richieri-Costa, A., Lidral, A.C., Murray, J.C., Moore, G.E.
and Stanier, P. (2004) TBX22 mutations are a frequent cause of cleft
palate. J. Med. Genet., 41, 68–74.
14. Zucchero, T.M., Cooper, M.E., Maher, B.S., Daack-Hirsch, S.,
Nepomuceno, B., Ribeiro, L., Caprau, D., Christensen, K., Suzuki, Y.,
Machida, J. et al. (2004) Interferon regulatory factor 6 (IRF6) gene
variants and the risk of isolated cleft lip or palate. N. Engl. J. Med., 351,
769–780.
15. Riley, B.M., Mansilla, M.A., Ma, J., Daack-Hirsch, S., Maher, B.S.,
Raffensperger, L.M., Russo, E.T., Vieira, A.R., Dode, C., Mohammadi, M.
et al. (2007) Impaired FGF signalling contributes to cleft lip and palate.
Proc. Natl Acad. Sci. USA, 104, 4512–4517.
16. Jugessur, A., Rahimov, F., Lie, R.T., Wilcox, A.J., Gjessing, H.K.,
Nilsen, R.M., Nguyen, T.T. and Murray, J.C. (2008) Genetic variants in
IRF6 and the risk of facial clefts: single-marker and haplotype-based
analyses in a population-based case–control study of facial clefts in
Norway. Genet. Epidemiol., 32, 413–424.
17. Van der Woude, A. (1954) Fistula labii inferioris congenita and its
association with cleft lip and palate. Am. J. Hum. Genet., 6, 244–256.
18. Bixler, D., Poland, C. and Nance, W.E. (1973) Phenotypic variation in the
popliteal pterygium syndrome. Clin. Genet., 4, 220–228.
19. Froster-Iskenius, U.G. (1990) Popliteal pterygium syndrome. J. Med.
Genet., 27, 320–326.
20. Bocian, M. and Walker, A.P. (1987) Lip pits and deletion 1q32-41.
Am. J. Med. Genet., 26, 437–443.
21. Murray, J.C., Nishimura, D.Y., Buetow, K.H., Ardinger, H.H.,
Spence, M.A., Sparkes, R.S., Falk, R.E., Gardner, R.J., Harkness, E.M.,
Glinski, L.P. et al. (1990) Linkage of an autosomal dominant clefting
syndrome (Van der Woude) to loci on chromosome 1q. Am. J. Hum.
Genet., 46, 486–491.
22. Sander, A., Schmelzle, R. and Murray, J. (1994) Evidence for a
microdeletion in 1q32-41 involving the gene for Van der Woude
syndrome. Hum. Mol. Genet., 3, 575–578.
23. Lees, M.M., Winter, R.M., Malcolm, S., Saal, H.M. and Chitty, L. (1999)
Popliteal pterygium syndrome: a clinical study of three families and report
of linkage to the Van der Woude syndrome locus on 1q32. J. Med. Genet.,
36, 888–892.
24. Schutte, B.C., Sander, A., Malik, M. and Murray, J.C. (1996) Reﬁnement
of the Van der Woude gene location and construction of a 3.5-Mb YAC
contig and STS map spanning the critical region in 1q32-q41. Genomics,
36, 507–514.
25. Schutte, B.C., Bjork, B.C., Coppage, K.B., Malik, M.I., Gregory, S.G.,
Scott, D.J., Brentzell, L.M., Watanabe, Y., Dixon, M.J. and Murray, J.C.
(2000) A preliminary gene map for the Van der Woude syndrome critical
region derived from 900 kb of genomic sequence at 1q32-q41. Genome
Res., 10, 81–94.
26. Schutte, B.C., Basart, A.M., Watanabe, Y., Lafﬁn, J.J.S., Coppage, K.,
Bjork, B.C., Daack-Hirsch, S., Patil, S., Dixon, M.J. and Murray, J.C.
(1999) Microdeletions at chromosome bands 1q32-q41 as a cause of Van
der Woude syndrome. Am. J. Med. Genet., 84, 145–150.
27. Lin, R., Mamane, Y. and Hiscott, J. (1999) Structural and functional
analysis of interferon regulatory factor 3: localization of the transctivation
and autoinhibitory domains. Mol. Cell Biol., 19, 2465–2474.
28. Taniguchi, T., Ogasawara, K., Takaoka, A. and Tanaka, N. (2001) IRF
family of transcription factors as regulators of host defense. Annu. Rev.
Immunol., 19, 623–655.
29. Tanaka, N., Kawakami, T. and Taniguchi, T. (1993) Recognition DNA
sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators
of cell growth and the interferon system. Mol. Cell Biol., 13, 4531–4538.
30. Darnell, J.E. Jr, Kerr, I.M. and Stark, G.R. (1994) Jac-STAT pathways and
transcriptional activation in response to IFNs and other extracellular
signaling proteins. Science, 264, 1415–1420.
31. Fujii, Y., Shimizu, T., Kusumoto, M., Kyogoku, Y., Taniguchi, T. and
Hakoshima, T. (1999) Crystal structure of an IRF-DNA complex reveals
novel DNA recognition and cooperative binding to a tandem repeat of
core sequences. EMBO J., 18, 5028–5041.
32. Escalante, C.R., Yie, J., Thanos, D. and Aggarwal, A.K. (1998) Structure
of IRF-1 with bound DNA reveals determinants of interferon regulation.
Nature, 391, 103–106.
33. Escalante, C.R., Brass, A.L., Pongubala, J.M.R., Shatova, E., Shen, L.,
Singh, H. and Aggarwal, A.K. (2002) Crystal structure of PU.1/IRF-4/
DNA ternary complex. Mol. Cell, 10, 1097–1105.
34. Qin, B.Y., Liu, C., Lam, S.S., Srinath, H., Delston, R., Correia, J.J.,
Derynck, R. and Lin, K. (2003) Crystal structure of IRF-3 reveals
mechanism of autoinhibition and virus-induced phosphoactivation. Nat.
Struct. Biol., 10, 913–921.
35. Item, C.B., Turhani, D., Thurnher, D., Yerit, K., Sinko, K., Wittwer, G.,
Adeyemo, W.L., Frei, K., Erginel-Unaltuna, N., Watzinger, F. and
Ewers, R. (2005) Van Der Woude syndrome: variable penetrance of a
novel mutation (p.Arg 84Gly) of the IRF6 gene in a Turkish family.
Int. J. Mol. Med., 15, 247–251.
36. Gunasekaran, K., Nagarajaram, H.A., Ramakrishnan, C. and Balaram, P.
(1998) Stereochemical punctuation marks in protein structures: glycine
and proline containing helix stop signals. J. Mol. Biol., 275, 917–932.
37. Ghassibe, M., Revencu, N., Bayet, B., Gillerot, Y., Vanwijck, R.,
Verellen-Dumoulin, C. and Vikkula, M. (2004) Six families with van der
Woude and/or popliteal pterygium syndrome: all with a mutation in the
IRF6 gene. J. Med. Genet., 41, e15.
544 Human Molecular Genetics, 2009, Vol. 18, No. 338. Richardson, R.J., Dixon, J., Malhotra, S., Hardman, M.J., Knowles, L.,
Boot-Handford, R.P., Shore, P., Whitmarsh, A. and Dixon, M.J. (2006)
IRF6 is a key determinant of the keratinocyte proliferation/differentiation
switch. Nat. Genet., 38, 1329–1334.
39. Ingraham, C.R., Kinoshita, A., Kondo, S., Yang, B., Sajan, S., Trout, K.J.,
Malik, M.I., Dunnwald, M., Goudy, S.L., Lovett, M. et al. (2006)
Abnormal skin, limb and craniofacial morphogenesis in mice
deﬁcient for interferon regulatory factor 6 (Irf6). Nat. Genet., 38,
1335–1340.
40. Bailey, C.M., Abbott, D.E., Margaryan, N.V., Khalkhali-Ellis, Z. and
Hendrix, M.J. (2008) Interferon regulatory factor 6 promotes cell cycle
arrest and is regulated by the proteasome in a cell cycle-dependent
manner. Mol. Cell Biol., 28, 2235–2243.
41. Knight, A.S., Schutte, B.C., Jiang, R. and Dixon, M.J. (2006)
Developmental expression analysis of the mouse and chick orthologues of
IRF6; the gene mutated in Van der Woude syndrome. Dev. Dyn., 235,
1441–1447.
42. Xu, X., Han, J., Ito, Y., Bringas, P. Jr, Urata, M.M. and Chai, Y. (2006)
Cell autonomous requirement for Tgfbr2 in the disappearance of the
medial edge epithelium during palatal fusion. Dev. Biol., 297, 238–248.
43. Brass, A.L., Kehrli, E., Eisenbeis, C.F., Storb, U. and Singh, H. (1996)
Pip, a lymphoid-restricted IRF, contains a regulatory domain that is
important for autoinhibition and ternary complex formation with the Ets
factor PU.1. Genes Dev., 10, 2335–2347.
44. Brass, A.L., Zhu, A.Q. and Singh, H. (1999) Assembly requirements of
PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using
fused dimers. EMBO J., 18, 977–991.
45. Marecki, S., Riendeau, C.J., Liang, M.D. and Fenton, M.J. (2001) PU.1
and multiple IFN regulatory factor proteins synergize to mediate
transcriptional activation of the human IL-1 beta gene. J. Immunol., 166,
6829–6838.
46. Rahimov, F., Marazita, M.L., Visel, A., Cooper, M.E., Hitchler, M.J.,
Rubini, M., Domann, F.E., Govil, M., Christensen, K., Bille, C. et al.
(2008) Disruption of an AP-2a binding site in an IRF6 enhancer is
associated with cleft lip. Nat. Genet., 40, 1341–1347.
47. Davies, A.F., Stephens, R.J., Olavesen, M.G., Heather, L., Dixon, M.J.,
Magee, A., Flinter, F. and Ragoussis, J. (1995) Evidence of a locus for
orofacial clefting on human chromosome 6p24 and STS content of the
region. Hum. Mol. Genet., 4, 121–128.
48. Davies, A.F., Imaizumi, K., Mirza, G., Stephens, R.S., Kuroki, Y.,
Matsuno, M. and Ragoussis, J. (1998) Further evidence for the
involvement of human chromosome 6p24 in the aetiology of orofacial
clefting. J. Med. Genet., 35, 857–861.
49. Schorle, H., Meier, P., Buchert, M., Jaenisch, R. and Mitchell, P.J. (1996)
Transcription factor AP-2 essential for cranial closure and craniofacial
development. Nature, 381, 235–238.
50. Zhang, J., Hagopian-Donaldson, S., Serbedzija, G., Elsemore, J.,
Plehn-Dujowich, D., McMahon, A.P., Flavell, R.A. and Williams, T.
(1996) Neural tube, skeletal and body wall defects in mice lacking
transcription factor AP-2. Nature, 381, 238–241.
51. Shore, P. and Sharrocks, A.D. (1995) The ETS-domain transcription
factors Elk-1 and SAP-1 exhibit differential DNA binding speciﬁcities.
Nucleic Acids Res., 23, 4698–4706.
52. Crooks, G.E., Hon, G., Chandonia, J.M. and Brenner, S.E. (2004)
WebLogo: a sequence logo generator. Genome Res., 14, 1188–1190.
53. Whitmore, L. and Wallace, B.A. (2004) DICHROWEB, an online server
for protein secondary structure analyses from circular dichroism
spectroscopic data. Nucleic Acids Res., 32, W668–W673.
Human Molecular Genetics, 2009, Vol. 18, No. 3 545